(Q36872636)

16 August 2017

1 reference

title

Tuberculosis: vaccine and drug development (English)

1 reference

16 August 2017

1 reference

Masao Mitsuyama

1

1 reference

16 August 2017

David N McMurray

series ordinal

2

1 reference

16 August 2017

publication date

9 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

87 Suppl 1

1 reference

16 August 2017

page(s)

S10-3

1 reference

The Development and Impact of Tuberculosis Vaccines

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Tuberculosis vaccine development; from mouse to man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Advances in tuberculosis vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Immune responses to tuberculosis in developing countries: implications for new vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

The search for a tuberculosis vaccine: an elusive quest?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

The tuberculosis vaccine challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Safety issues regarding new vaccines for tuberculosis, with an emphasis on post-exposure vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Mouse and guinea pig models for testing new tuberculosis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

NIH pre-clinical screening program: overview and current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Synergistic Effect of Bacillus Calmette Guerin and a Tuberculosis Subunit Vaccine in Cationic Liposomes: Increased Immunogenicity and Protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Improved protection by recombinant BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

DNA augments antigenicity of mycobacterial DNA-binding protein 1 and confers protection against Mycobacterium tuberculosis infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

The immunogenicity and protective efficacy of Mtb8.4/hIL-12 chimeric gene vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Combined DNA vaccine encapsulated in microspheres enhanced protection efficacy against Mycobacterium tuberculosis infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Vaccine strategies against latent tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

The role of "go no-go" decisions in TB vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2007.05.006

10.1016/J.TUBE.2007.05.006

7 January 2021

Identifiers

DOI

1 reference

release_jk6c3ng7gjdolf76usnmbukkzu

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jk6c3ng7gjdolf76usnmbukkzu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference